Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Yi Miao, Wenyu Li, Kaiyang Ding, Fei Li, Xiaojing Yan, Xiaoxi Zhou, Caixia Li, Guohui Cui, Liqun Zou, Bing Xiu, Xiangxiang Zhou, Liansheng Zhang, Fuling Zhou, Hongmei Jing, Jianli Wang, Ziheng Guo, Jianyong Li

Blood (2024) 144 (Supplement 1): 6372.

https://doi.org/10.1182/blood-2024-201339

Published: 2024

Journal Articles

Efficacy and Safety Study of Chimeric Antigen Receptor-T Cell Therapy for People with Relapsed/Refractory Follicular Lymphoma

Ting Xu, Liangyu Zeng, Depei Wu, Caixia Li

Blood (2024) 144 (Supplement 1): 7801.

https://doi.org/10.1182/blood-2024-200310

Published: 2024

Journal Articles

Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Yufu Li, Wei Xu, Caixia Li, Pengcheng He, Wei Yang, Xiangmin Tong, Ying Wang, Hongchan Zhang, Caixia Sun, Zejuan Sheng, Jean Fan, Jianyong Li

Blood (2024) 144 (Supplement 1): 3036.

https://doi.org/10.1182/blood-2024-202976

Published: 2024

Journal Articles

Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era

Haiwen Huang, Mao Jin, Caixia Li, Zhengming Jin, Depei Wu

Blood (2024) 144 (Supplement 1): 1676.

https://doi.org/10.1182/blood-2024-201884

Published: 2024

Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Blood (2023) 142 (Supplement 1): 1900.

https://doi.org/10.1182/blood-2023-183071

Published: 2023

Journal Articles

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Jing Lu, Shengli Xue, Ying Wang, Hai-Ping Dai, Xuefeng He, Xiaohui Hu, Miao Miao, Huiying Qiu, Han Yue, Caixia Li, Depei Wu, Suning Chen

Blood (2023) 142 (Supplement 1): 970.

https://doi.org/10.1182/blood-2023-181347

Published: 2023

Journal Articles

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 3048.

https://doi.org/10.1182/blood-2023-182812

Published: 2023

Journal Articles

Survival Outcome of Autologous or Allogeneic Stem Cell Transplantation in 49 Patients with Extranodal NK/T-Cell Lymphoma

Mao Jin, Sicheng Ai, Tao You, Xiao Ma, Feng Chen, Caixia Li, Zhengming Jin, Depei Wu, Haiwen Huang

Blood (2023) 142 (Supplement 1): 6215.

https://doi.org/10.1182/blood-2023-186001

Published: 2023

Journal Articles

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

Caixia Li, Jia Wei, Keshu Zhou, Peng Liu, He Huang, Fei Li, Yujun Dong, Qingqing Cai, Shenmiao Yang, Xinyou Zhang, Hui Zhou, Lu Zhang, Zaixing Shi, Zhiyu Liang, Binghao Wu, Depei Wu

Blood (2022) 140 (Supplement 1): 6717–6718.

https://doi.org/10.1182/blood-2022-171046

Published: 2022

Journal Articles

Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ying Zhang, Jiaqi Li, Xiangping Zong, Jin Zhou, Sixun Jia, Hongzhi Geng, Xiaoyan Lou, Liqing Kang, Lei Yu, Depei Wu, Caixia Li

Blood (2021) 138 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2021-146293

Published: 2021

Journal Articles

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Blood (2021) 138 (Supplement 1): 1755.

https://doi.org/10.1182/blood-2021-152927

Published: 2021

Journal Articles

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Caixia Li, Changfeng Zhang, PhD, Ying Zhang, Xiaoyan Lou, Jinfang Zhang, Jia Chen, MD, Xiaochen Chen, Liqing Kang, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 4097.

https://doi.org/10.1182/blood-2019-127928

Published: 2019

Journal Articles

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

Caixia Li, Changfeng Zhang, PhD, Xiaochen Chen, Ying Zhang, Jia Chen, MD, Liqing Kang, Xiaoyan Lou, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 5313.

https://doi.org/10.1182/blood-2019-126821

Published: 2019

Journal Articles

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Liqing Kang, Xiaowen Tang, Nan Xu, Minghao Li, Jingwen Tan, Wei Qi, Zhou Yu, Xiaoyan Lou, Shengli Xue, Xin Li, MD, Jian Zhang, MD, Jia Chen, MD, Zhenkun Wang, PhD, Caixia Li, Fu Cheng Cheng, MD PhD, Depei Wu, MD PhD, Lei Yu, MD PhD

Blood (2019) 134 (Supplement_1): 2621.

https://doi.org/10.1182/blood-2019-132067

Published: 2019

Journal Articles

Possible Factors on Efficacy and Safety of CAR-T Therapy in Relapsed or Refractory Aggressive B-Cell Lymphoma

Haiwen Huang, Yibin Jiang, Zhengming Jin, Caixia Li, Depei Wu

Blood (2018) 132 (Supplement 1): 5386.

https://doi.org/10.1182/blood-2018-99-114727

Published: 2018

Journal Articles

Outcome of Allogeneic Stem Cell Transplantation in T Cell Lymphoblastic Lymphoma

Caixia Li, PhD, Dan Yang, Jia Chen, MD, Pu Wang, Ying Zhang, Depei Wu, MD

Blood (2017) 130 (Supplement 1): 5535.

https://doi.org/10.1182/blood.V130.Suppl_1.5535.5535

Published: 2017

Journal Articles

Primary Analysis of the Effect of Hematopoietic Stem Cell Transplantation in the Treatment of 98 Cases of T Cell Lymphoma

Caixia Li, PhD, Dan Yang, Xiaochen Chen, Tong Wang, Qiu Zou, Caihong Gu, Haiwen Huang, Depei Wu, MD PhD

Blood (2016) 128 (22): 5857.

https://doi.org/10.1182/blood.V128.22.5857.5857

Published: 2016

Journal Articles

TIM3 Dynamically Expressed on Peripheral Blood NK Cells in Acute Myeloid Leukemia Patients: The Expression Decreased When Untreated, and Restored While Disease Improved

Caixia Li, PhD, Xiaochen Chen, Caihong Gu, Tong Wang, Qiu Zou, Dan Yang, Depei Wu, MD PhD

Blood (2016) 128 (22): 5243.

https://doi.org/10.1182/blood.V128.22.5243.5243

Published: 2016

Journal Articles

The Expression and Mechanism of Tim3 and PD-1 in Patients with Acute Myeloid Leukemia

Caixia Li, PhD, Xiao Yu, Caihong Gu, Chao Ma, Hong Liu, Wang Tong, Qiu Zou, Lu Ye, Xiaochen Chen, Wu Depei, MD

Blood (2015) 126 (23): 4948.

https://doi.org/10.1182/blood.V126.23.4948.4948

Published: 2015

Journal Articles

TIM-3 Is Highly Expressed On Blast Cells In Patients With Acute Myeloid Leukemia

Caixia Li, Xiao Yu, Yibei Zhu, Xiaojin Wu, Xiao Ma, Hong Liu, Lu Ye, Chao Ma, Rui Xia, Aining Sun, Changgeng Ruan, MD, PhD, Suning Chen, Wu Depei

Blood (2013) 122 (21): 4931.

https://doi.org/10.1182/blood.V122.21.4931.4931

Published: 2013

NARROW

The Treatment Pathways, Patient Characteristics and Outcomes in Patients with CD30-Expressing Lymphoma from China: A Multi-Center, Non-Interventional, Retrospective Study

Efficacy and Safety Study of Chimeric Antigen Receptor-T Cell Therapy for People with Relapsed/Refractory Follicular Lymphoma

Phase 1 Study of TT-01488, a Novel, Non-Covalent, Reversible BTK Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies

Clinical Characteristics and Treament Outcomes of 104 Cases of Extranodal NK/T-Cell Lymphoma Undergoing Primary Treatment in Novel Agents Era

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Comparing the Efficacy and Safety of Venetoclax Combined with Decitabine Versus Conventional Chemotherapy As Induction Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia - Interim Analysis of a Multicenter, Randomized, Phase 2b Trial

Development and Validation of a Machine-Learning Model to Predict POD24 Risk of Follicular Lymphoma

Survival Outcome of Autologous or Allogeneic Stem Cell Transplantation in 49 Patients with Extranodal NK/T-Cell Lymphoma

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

Chimeric Antigen Receptor T Cell Targeting to CD19 and CD22 Combined with Anti-PD-1 Antibody Induce High Response in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Relative Depletion of Soluble Interleukin 6 Receptors Abolished the Development of Cytokine Release Syndrome after CART19/22 and Lenalidomide Treatment for Lymphoma

shRNA-Interleukin-6 Modified CD19-Specific Chimeric Antigen Receptor T Cell Significantly Improves the Safety in Acute Lymphoblastic Leukemia

Possible Factors on Efficacy and Safety of CAR-T Therapy in Relapsed or Refractory Aggressive B-Cell Lymphoma

Outcome of Allogeneic Stem Cell Transplantation in T Cell Lymphoblastic Lymphoma

Primary Analysis of the Effect of Hematopoietic Stem Cell Transplantation in the Treatment of 98 Cases of T Cell Lymphoma

TIM3 Dynamically Expressed on Peripheral Blood NK Cells in Acute Myeloid Leukemia Patients: The Expression Decreased When Untreated, and Restored While Disease Improved

The Expression and Mechanism of Tim3 and PD-1 in Patients with Acute Myeloid Leukemia

TIM-3 Is Highly Expressed On Blast Cells In Patients With Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only